Mechanisms of resistance to anti-EGFR therapy in colorectal cancer. - Abstract - Europe PMC
Oncogenic mutations as predictive factors in colorectal cancer | Oncogene
EGFR signaling in colorectal cancer: a clinical perspective | GICTT
Identification of actionable alterations in colorectal cancer are leading to the development of novel treatment strategies - Mayo Clinic
EGFR Inhibitor as Second-Line Therapy in a Patient With Mutant RAS Metastatic Colorectal Cancer: Circulating Tumor DNA to Personalize Treatment | JCO Precision Oncology
Colorectal Cancer: How Emerging Molecular Understanding Affects Treatment Decisions
Diagrammatic model of EGFR pathway-modulated macrophage polarization in... | Download Scientific Diagram
Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies | SpringerLink
EGFR Signaling in Colorectal Carcinoma
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR | Nature
Precision Medicine in Metastatic Colorectal Cancer: Relevant Carcinogenic Pathways and Targets-PART 1: Biologic Therapies Targeting the Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor
Comprehensive review of targeted therapy for colorectal cancer | Signal Transduction and Targeted Therapy
Epidermal growth factor receptor (EGFR)-related signaling pathway in... | Download Scientific Diagram
Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives - Annals of Oncology
EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer | British Journal of Cancer
The efficacy of anti-EGFR therapy in treating metastatic colorectal cancer differs between the middle/low rectum and the left-sided colon | British Journal of Cancer
Signaling pathways involved in colorectal cancer progression | Cell & Bioscience | Full Text
BRAF Mutation in Colorectal Cancer Anita Turk, MD; Dustin Deming, MDDivision of Hematology and Oncology,Department of MedicineUniversity of Wisconsin-Madison School of Medicine and Public Health and University of Wisconsin Carbone Cancer Center,
Frontiers | The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells
Concomitant Tumor Expression of EGFR and TATI/SPINK1 Associates with Better Prognosis in Colorectal Cancer | PLOS ONE
Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies | Journal of Experimental & Clinical Cancer Research | Full Text
Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC) - European Journal of Cancer
Colorectal adenocarcinoma‐derived EGFR mutants are oncogenic and sensitive to EGFR‐targeted monoclonal antibodies, cetuximab and panitumumab - Kim - 2020 - International Journal of Cancer - Wiley Online Library
Comprehensive review of targeted therapy for colorectal cancer | Signal Transduction and Targeted Therapy
EGFR signaling in colorectal cancer: a clinical perspective | GICTT
EGFR, HER2, and HER3 protein expression in paired primary tumor and lymph node metastasis of colorectal cancer | Scientific Reports
